A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
The purpose of this study is to test the effects, good or bad, of an investigational new drug called VLS-101 in participants with relapsed and/or refractory hematologic cancers. This is the first study to test the drug in people. This study tests different doses of the drug to see which dose is safer in people. Another purpose of the study is to see how well the study drug shrinks or controls your cancer. If you decide to participate and you qualify for the study, you will receive the study drug intravenously (IV) every 3 weeks.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), or Richter transformation lymphoma (RTL)
Men and women at least 18 years of age who have been diagnosed with relapsed (returned after the most recent treatment regimen) and/or refractory (has not responded to the most recent treatment regimen) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), or Richter transformation lymphoma (RTL)
18 - 99
Healthy Volunteers Needed
Duration of Participation
You may receive the study drug until your disease gets worse, the side effects become too severe, or the study is stopped by the funder. After you finish taking the study drug, the investigator will continue to watch you for side effects and follow your condition for up to 3 years.
Clinical Trials Information Line